IBT B Stock Overview
A clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Infant Bacterial Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 56.00 |
| 52 Week High | SEK 135.00 |
| 52 Week Low | SEK 21.70 |
| Beta | 1.06 |
| 1 Month Change | 46.60% |
| 3 Month Change | 65.68% |
| 1 Year Change | -37.92% |
| 3 Year Change | -9.24% |
| 5 Year Change | -60.84% |
| Change since IPO | -47.42% |
Recent News & Updates
Recent updates
Will Infant Bacterial Therapeutics (STO:IBT B) Spend Its Cash Wisely?
Dec 05
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Aug 02Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment
May 02Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans
Apr 03Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation
Sep 16We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
May 11We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate
Sep 23We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely
Apr 07We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Dec 15We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Aug 25We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate
May 06Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)
Feb 07Shareholder Returns
| IBT B | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 4.9% | -0.4% | -2.0% |
| 1Y | -37.9% | -1.8% | 4.4% |
Return vs Industry: IBT B underperformed the Swedish Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: IBT B underperformed the Swedish Market which returned 4.4% over the past year.
Price Volatility
| IBT B volatility | |
|---|---|
| IBT B Average Weekly Movement | 13.7% |
| Pharmaceuticals Industry Average Movement | 8.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: IBT B's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: IBT B's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 10 | Staffan Stromberg | www.ibtherapeutics.com |
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies `to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants.
Infant Bacterial Therapeutics AB (publ) Fundamentals Summary
| IBT B fundamental statistics | |
|---|---|
| Market cap | SEK 754.40m |
| Earnings (TTM) | -SEK 144.03m |
| Revenue (TTM) | SEK 5.00k |
Over9,999x
P/S Ratio-5.2x
P/E RatioIs IBT B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBT B income statement (TTM) | |
|---|---|
| Revenue | SEK 5.00k |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 5.00k |
| Other Expenses | SEK 144.04m |
| Earnings | -SEK 144.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -10.69 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,880,640.00% |
| Debt/Equity Ratio | 0% |
How did IBT B perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 03:08 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Infant Bacterial Therapeutics AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Taylor Feehley | Chardan Capital Markets, LLC |